Microphage Inc. Concludes Pivotal Clinical Study of World’s First Test Designed to Rapidly Identify Bacterial Infections and Antibiotic Susceptibility without Costly Equipment

LONGMONT, Colo.--(BUSINESS WIRE)-- MicroPhage announced today that it has concluded a pivotal study of the ‘Microphage MRSA/MSSA Blood Culture Test’, the first of its instrument-free, rapid tests based on patented Bacteriophage Amplification technology. Data from the pivotal study will support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification, which the Company will be submitting as soon as possible. With CE Mark already in place, MicroPhage expects to begin commercial shipments this month.